Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repairing Peri-Anal Fistulas with regenerative cell therapeutics (REP-PAF)
2022-502659-73-01Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Feb 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous adipose-derived stem/stromal cells in anal fistula (2 arms), sponsored by University Hospital Odense. Primary endpoint: Clinical healing at 6 and 12 months. Planned start Feb 2024; status: authorised.
02
Drugs
autologous adipose-derived stem/stromal cells
03
Conditions
anal fistula
Beyond the preview
Go deeper on 2022-502659-73-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502659-73-01.